APP and Alzheimer disease: TLR4 inhibition provides neuroprotection and promotes a microglial switch from the inflammatory M1 phenotype to the protective M2 phenotype in APP/PS1 transgenic AD mice, accompanied by a reduction of MyD88, NF-κB, and NLRP3 (Cui et al., 2020).